1-2 of 2
Adolfo De La Fuente Burguera
Close
Sort by
Journal Articles

Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive Chemotherapy for Patients Aged ≥ 60 Years Old with FLT3 Mutated Acute Myeloid Leukemia

Gaspar Aspas Requena, Pierre Yves Dumas, Rebeca Rodriguez Veiga, Sarah Bertoli, Cristina Gil, Celestine Simand, Fernando Jesús Ramos-Ortega, Pierre Peterlin, Josefina Serrano, Rudy Birsen, Teresa Bernal Del Castillo, Emmanuelle Tavernier, Mar Tormo, Martin Carre, Maria Jose Garcia, Adrien Contejean, Rosalia Riaza Grau, Corentin Orvain, Jose Antonio Pérez-Simón, Esther Perez Santaolla, Lauren Veronese, Beatriz De Rueda Ciller, Eric Delabesse, Antonio Gutiérrez, Ariane Mineur, Adolfo De La Fuente Burguera, Romain Guieze, Arnaud Pigneux, Pau Montesinos, Christian Recher, David Matínez-Cuadrón
Journal: Blood
Blood (2023) 142 (Supplement 1): 2864.
https://doi.org/10.1182/blood-2023-190128
Published: 2023
Journal Articles

Trial in Progress: A Phase 1b Single-Arm, Open-Label Study of Emavusertib (CA-4948) in Combination with Azacitidine and Venetoclax in Acute Myeloid Leukemia Patients in Complete Response with Measurable Residual Disease

Adolfo De La Fuente Burguera, Claudio Cerchione, Sebastian Scholl, Jan Moritz Middeke, Gaurav S Choudhary, Reinhard von Roemeling, Uwe Platzbecker
Journal: Blood
Blood (2023) 142 (Supplement 1): 5975.
https://doi.org/10.1182/blood-2023-190125
Published: 2023